Eisai Pharmatechnology, Inc. Breaks Ground on $40 Million Facility at Research Triangle Park
Research Triangle Park, NC (May 1, 1996) -- Eisai Pharmatechnology, Inc. (EPI) today broke ground on an 85,000-foot drug formulation research and development and pharmaceutical manufacturing facility to be located at the Research Triangle Park in Durham, North Carolina. Joined by Gov. James B. Hunt, Jr., Becky Heron, chair of the Durham County Board of Commissioners, and scores of business, government and education leaders, Haruo Naito, President and CEO of Eisai Co., Ltd., heralded the project as a "victory for Eisai, Durham County and North Carolina."
Scheduled to be completed in August 1997, the $40 million facility will be located on approximately 52 acres of land. Pharmaceutical formulation research will start in early 1998 with approximately 40 employees. It is projected that the facility employment will increase to 60 people when commercial operations begin in early 1999.
According to President Naito, the factors in Eisai's choice of Research Triangle Park included the skilled local work force and the ongoing research at public and private institutions in the area. "We are delighted to join such a vibrant community and are grateful for the assistance we have received from the State of North Carolina, Durham County and the Research Triangle Foundation," said President Naito.
"This company is making important strides in the health care industry," said Gov. Hunt. "We appreciate Eisai's vote of confidence in Durham County, Research Triangle Park and North Carolina as the company continues to conduct research that will improve our live."
Eisai plans to manufacture Eisai's Alzheimer's disease treatment, ARICEPT(TM) (donepezil hydrochloride), at the facility. The treatment will be EPI's first commercial product. Eisai's Alzheimer's treatment is a novel and selective acetylcholinesterase inhibitor synthesized in Japan. Currently in Phase III clinical trials in Europe, Canada, Australia, New Zealand and South Africa, the treatment will enter Phase III trials in Japan later this year. An application for approval was submitted to the FDA in late March. Eisai also has a proton pump inhibitor for the treatment of peptic ulcers in Phase III clinical trials in the U.S. and Europe.
Eisai Pharmatechnology, Inc. (EPI) is an affiliate of Eisai Co., Ltd. of Tokyo. Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of over $2.9 billion in fiscal year 1994 with more than $400 million spent for research and development.
ARICEPT(TM)is a trademark of Eisai Co., Ltd.